Lv12
45 积分 2022-05-29 加入
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment
6小时前
待确认
Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib
1天前
已完结
PL04.10 Osimertinib With or Without Savolitinib as 1L in De Novo MET Aberrant, EGFRm Advanced NSCLC (CTONG 2008): A Phase II Trial
17天前
已关闭
PL04.10 Osimertinib With or Without Savolitinib as 1L in De Novo MET Aberrant, EGFRm Advanced NSCLC (CTONG 2008): A Phase II Trial
17天前
已关闭
Unraveling the Significance of MET Focal Amplification in Lung Cancer: Integrative NGS, FISH, and IHC Investigation
23天前
已完结
The landscape of EGFR pathways and personalized management of non-small-cell lung cancer
23天前
已完结
MET receptor in oncology: From biomarker to therapeutic target
24天前
已完结
MET receptor in oncology: From biomarker to therapeutic target
24天前
已关闭
Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer
28天前
已关闭
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer
1个月前
已完结
Computer Simulations of the Impedance Response of Lithium Rechargeable Batteries
皖公网安备34019202002308
